The Journal of Experimental Medicine
StemCell Technologies
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online April 2, 2007
doi:10.1084/jem.20061699
The Journal of Experimental Medicine, Vol. 204, No. 4, 879-891
The Rockefeller University Press, 0022-1007 $30.00
© 2007 Loeser et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loeser, S.
Right arrow Articles by Penninger, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loeser, S.
Right arrow Articles by Penninger, J. M.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells

Stefanie Loeser1, Karin Loser2, Martijn S. Bijker3, Manu Rangachari1, Sjoerd H. van der Burg4, Teiji Wada1, Stefan Beissert2, Cornelis J.M. Melief3, and Josef M. Penninger1

1 Institute of Molecular Biotechnology of the Austrian Academy of Science, 1030 Vienna, Austria
2 Department of Dermatology and Interdisciplinary Center of Clinical Research, University of Münster, D-48149 Münster, Germany
3 Department of Immunohematology and Blood Transfusion and 4 Department of Clinical Oncology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands

CORRESPONDENCE Josef M. Penninger: Josef.penninger{at}imba.oeaw.ac.at

The concept of tumor surveillance implies that specific and nonspecific components of the immune system eliminate tumors in the early phase of malignancy. Understanding the biochemical mechanisms of tumor immunosurveillance is of paramount significance because it might allow one to specifically modulate spontaneous antitumor activity. We report that inactivation of the E3 ligase Casitas B cell lymphoma-b (Cbl-b) confers spontaneous in vivo rejection of tumor cells that express human papilloma virus antigens. Moreover, cbl-b–/– mice develop significantly fewer ultraviolet B (UVB)–induced skin malignancies and reject UVB-induced skin tumors. CD8+ T cells were identified as key players in the spontaneous tumor rejection response. Loss of Cbl-b not only enhances antitumor reactivity of CD8+ T cells but also occurs in the absence of CD4+ T cells. Mechanistically, cbl-b–/– CD8+ T cells are resistant to T regulatory cell–mediated suppression and exhibit enhanced activation and rapid tumor infiltration. Importantly, therapeutic transfer of naive cbl-b–/– CD8+ T cells is sufficient to mediate rejection of established tumors. Even up to 1 yr after the first encounter with the tumor cells, cbl-b–/– mice carry an "anticancer memory." These data identify Cbl-b as a key signaling molecule that controls spontaneous antitumor activity of cytotoxic T cells in different cancer models. Inhibition of Cbl-b is a novel approach to stimulate long-lasting immunity against cancer.


Abbreviations used: Cbl-b, Casitas B cell lymphoma-b protein; HPV, human papilloma virus.

K. Loser and M.S. Bijker contributed equally to this work.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Arming antitumor T cells
Hema Bashyam
J. Exp. Med. 2007 204: 696. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS